In the context of studying angiogenesis in NB, Klingenber’s research group used the CAM assay to investigate the potential therapeutic targeting of angiopoietin-2 (Ang-2) in human NBs. This evidence concerns the gene ANGPT2 and Nijmegen breakage syndrome.